Wire · regulatory
Tandem's FDA Clearance Of Tandem Mobi Tubeless Sets Up Competitive Race In 2027 ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 November 2026 · Fusion42 review
Tandem received FDA clearance for its Tandem Mobi tubeless insulin pump, positioning the company to intensify competition in the diabetes device market by 2027.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 13 Nov 2026 and 16 Nov 2026.
◆ ◆ The Wire takeaway
You must act fast as FDA clearance has opened the US diabetes device market to new competition. Prepare your product roadmap and market strategy now to keep pace with Tandem's growing presence.
◆ Coverage
2 sources · first reported 13 Nov 2026 · latest 16 Nov 2026
◆ Related on Wire
◆ Topics